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LETTERS
Adventitious
Viruses and
Smallpox Vaccine
To the Editor: Recently, Murphy
and Osburn (1) strongly argued for
testing old smallpox vaccine stocks
made in animal skin for adventitious
infectious agents such as viruses,
mycoplasmas, and eventually, prions.
Their argument appears clearly justi-
fied after unexpected cases of
myopericarditis occurred during
recent campaigns of smallpox vacci-
nations in the United States (2).
To the long list of bovine viruses
cited in this paper, it seems necessary
to add another, the pseudocowpox
virus, a widespread parapoxvirus that
may infect humans. During the 1960s,
this virus was identified in vaccine
lymph from a heifer at the Institut
Pasteur, Paris (3).
In humans, this virus is responsible
for limited skin lesions, more fre-
quently in immunocompromised
patients. Mainly farmers and butchers
are affected. Pseudocowpox virus is
easily differentiated from orthopox-
viruses such as vaccinia virus by the
virus’s peculiar form on transmission
electron microscopy scan, but poly-
merase chain reaction is probably the
best detection method (4). In fact,
many other more hazardous viruses
may be found in the oldest stocks of
smallpox vaccine and deserve more
attention than previously considered.
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*Virus Laboratory, Brest, France
References
1.  Murphy FA, Osburn BI. Adventitious
agents in smallpox vaccine in strategic
national stockpile. Emerg Infect Dis.
2005;11:1086–9.
2. Arness MK, Eckart RE, Love SS, Atwood
JE, Wells TS, Engler RJ, et al.
Myopericarditis following smallpox vacci-
nation. Am J Epidemiol. 2004;160:642–51.
3.  Pournaki R, Vieuchange J, Lépine P,
Fasquelle R. Isolement d’un virus distinct
du virus vaccinal au cours de passages
d’une lymphe vaccinale de génisse. Ann
Inst Pasteur. 1964;107:173–83.
4.  Inoshima Y, Morooka A, Sentsui H.
Detection and diagnosis of parapoxvirus by
the polymerase chain reaction. J Virol
Methods. 2000;84:201–8.
Address for correspondence: Claude Chastel,
Laboratoire de Virologie, Faculté de Médecine,
F-29 200, Brest, France; fax: 33-2-98-01-64-
74; email:chastelc@aol.com
Fluoroquinolone
Use in Food
Animals
To the Editor: Two recent articles
(1,2) show that fluoroquinolone use in
food animals is associated with infec-
tions by antimicrobial drug–resistant
strains of Campylobacter in humans.
These infections cause problems in
treating illnesses as well as increased
rates of illness and death (3). Despite
a large body of scientific evidence and
a judicial review (1–3) that show
harmful results in many persons,
some members of the poultry and
pharmaceutical industries argue that
fluoroquinolone use in food animals
has no adverse effects in humans (4)
and continue to supply these drugs for
use in poultry (2,5). The use of these
drugs has caused rapidly increasing
resistance rates in most countries. In
the United States, 19% of
Campylobacter isolates from humans
are now ciprofloxacin resistant (2),
and resistance rates >80% are seen in
Spain (5). By contrast, in Australia,
where fluoroquinolones were never
approved for use in food animals,
domestically acquired infections with
fluoroquinolone-resistant  Campylo-
bacter spp. are rarely found in humans
(6). Drug-resistant Escherichia coli
is also of concern. In Spain, humans
frequently acquire fluoroquinolone-
resistant E. coli associated with fluo-
roquinolone use in poultry (7).
In the United States, better controls
in meat and poultry slaughter and pro-
cessing, as well as improved food-
safety education campaigns, have
resulted in 28% fewer Campylobacter
infections annually since 1996 (8).
However,  ≈1.8 million persons (600
per 100,000) are likely to contract
symptomatic  Campylobacter infec-
tions per year (3,8), and fluoro-
quinolone resistance is now 19% (2).
Thus, the risk of a person’s contracting
fluoroquinolone-resistant Campylo-
bacter infection is 114 per 100,000
per year. If 80% of Campylobacter
infections are foodborne (3), and 90%
of these infections are acquired from
poultry (9), then ≈82 of 100,000 per-
sons per will contract ciprofloxacin-
resistant  Campylobacter infections
from poultry each year. Most persons
with Campylobacter infections would
not benefit from antimicrobial drug
therapy. However, if only 10% of
infected persons would benefit from
antimicrobial drug therapy, fluoro-
quinolone use in poultry could cause
≈82 persons per million to have a
compromised response to therapy. In
the United States (population 300 mil-
lion), this number translates to
>24,000 persons annually.
Data on the number of animals that
receive fluoroquinolones are difficult
to find. Bayer (manufacturer of the
only fluoroquinolone used in poultry
in the United States) states that Baytril
(enrofloxacin) is used in <1% of US
broiler flocks (4). This statistic allows
us to estimate how many persons will
potentially have an adverse outcome
compared to the number of animals
receiving fluoroquinolones. If 24,000
persons in the United States have an
adverse outcome annually after <84
million chickens (1% of 8.4 billion)
are treated with enrofloxacin, then
≈285 persons are at risk of having an
adverse outcome for every 1 million
chickens treated. 
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